Trial · NCT03574402
Phase II Umbrella Study Directed by Next Generation Sequencing
NCT03574402, Phase 2, Unknown, Guangdong Association of Clinical Trials
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Umbrella Study Directed by Next Generation Sequencing. Trials, record NCT03574402. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03574402
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Umbrella Study Directed by Next Generation Sequencing
- NCT number
- NCT03574402
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Guangdong Association of Clinical Trials
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Avitinib Maleate, Afatinib, Crizotinib, X-396, Chidamide, Pyrotinib Maleate, AZD3759, Pirotinib, Nimotuzumab, Pemetrexed, Cisplatin, Sintilimab, Gemcitabine, Gemcitabine, Carboplatin
- First posted
- 2018-07-02
- Last updated
- 2022-12-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response rate (RR) | 24 months | RECIST version 1.1 |
| Secondary | Progression-free survival (PFS) | 24 months | RECIST version 1.1 |
| Secondary | Overall survival (OS) | 48 months | Overall Survival is defined as the time from first dose to death due to any cause. Through the follow-up within 30 days after study completion or termination of the last subject, death and date of death will be checked for subject alive during treatment period |
| Secondary | Disease control rate（DCR） | 24 months | RECIST version 1.1 |
| Secondary | Duration of response (DOR) | 24 months | RECIST version 1.1 |
| Secondary | Toxicity (number of patients with treatment-related AE as assessed by CTCAE v4.03) | 24 months | number of patients with treatment-related AE as assessed by CTCAE v4.03 |
| Secondary | Health-Related Quality of Life (HRQOL) | 24 months | EORTC-LC13 |
| Secondary | To explore the mechanism of drug resistance in the treatment of specific gene mutation | 24 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03574402
GET https://conductscience.org/api/trials/v1/NCT03574402/registered